The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BLGO | -33.33% | -7.37% | -1.52% | -75% |
| S&P | +13.95% | +78.35% | +12.25% | +366% |
BioLargo, Inc. engages in the provision of technology solutions for odor and moisture control, disinfection, and water treatment. It operates through the following segments: ONM Environmental, BLEST, BioLargo Water, Clyra Medical and Corporate Operations. The ONM Environmental segment manufactures and sells odor and VOC control products and services, including its flagship product, CupriDyne Clean. The BLEST segment offers professional engineering services through its internal business units. The BioLargo Water is a Canadian division which focuses on commercializing AOS systems. The Clyra Medical segment focuses on the advanced wound care industry. The Corporate Operations segment supports the operating segments with legal, accounting, human resources, and other related services. The company was founded in 1989 and is headquartered in Westminster, CA.
No news articles found for BioLargo.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.10M | -74.6% |
| Gross Profit | $372.00K | -78.4% |
| Gross Margin | 33.73% | -5.9% |
| Market Cap | $52.35M | -25.6% |
| Market Cap / Employee | $1.19M | 0.0% |
| Employees | 44 | 0.0% |
| Net Income | -$7,244.00K | -583.4% |
| EBITDA | -$3,246.00K | -226.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.55M | 17.1% |
| Accounts Receivable | $761.00K | -76.3% |
| Inventory | 0.4 | 71.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.46M | 119.2% |
| Short Term Debt | $1.35M | 341.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -101.26% | -76.1% |
| Return On Invested Capital | -90.77% | -163.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2,792.00K | -68.3% |
| Operating Free Cash Flow | -$2,759.00K | -70.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 6.67 | 9.41 | 8.15 | 5.94 | -48.99% |
| Price to Sales | 3.22 | 5.11 | 4.44 | 4.84 | 27.27% |
| Price to Tangible Book Value | 6.70 | 9.45 | 8.19 | 5.96 | -48.79% |
| Enterprise Value to EBITDA | -34.51 | -45.33 | -34.43 | -14.86 | -77.42% |
| Return on Equity | -30.6% | -40.0% | -52.8% | -129.8% | 379.80% |
| Total Debt | $2.55M | $3.05M | $3.67M | $3.81M | 166.62% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
